CTS Clinical and Translational Science: The Bioequivalence of Fixed-Dose Combination Tablets of Bisoprolol and Ramipril and its Drug-Drug Interaction Potential
Transitioning Novel Scientific Workflows to Routine Bioanalysis
Join Dr. Anahita Keyhani for a discussion on proactive, effective, and efficient bioanalytical project management, and the positive impact it can have on your drug development program.
Topics covered include:
- The framework for successful bioanalytical support at various phases and for different types of studies
- Bioanalytical critical control points (operational, logistical, technical, and scientific) to proactively manage for successful project progression
- Bioanalytical communication flow and key stakeholders for different types of studies
You may also be interested in the following:
- Fact Sheet: Clinical Sample Kits
- Webpages: Bioanalytical Services
- Webinar: Critical Sample Handling Processes for Preclinical and Clinical Studies
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Safety Pharmacology ― Key Considerations for a Successful Study
In this edition of The Altascientist titled Safety Pharmacology Guidelines and Practices, discover how to reduce the use of test animals, save time, and ensure quality data by:
- Combining safety pharmacology studies when appropriate
- Including safety pharmacology endpoints in toxicology studies
Read The Altascientist
Speak with our experts to learn more about our combined cardiovascular/respiratory safety pharmacology capabilities.
You may also be interested in the following:
- Webpage: Preclinical Services
- Fact Sheet: Safety Pharmacology
- Podcast: Science, 3Rs, and Animal Welfare with Dr. Megan R. LaFollette from 3RNA
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
The Many Faces of Recreational Drug Use
The Issue of Opioid aBUSE
A growing public health concern, opioid abuse has been intensified by the COVID-19 pandemic.
The Next Trip with Altasciences and DevelRX
In this podcast episode, experts from Altasciences and DevelRX examine the preclinical, clinical, and regulatory requirements and strategies that second generation psychedelics may utilize to differentiate their pharmacological profile, and strategically demonstrate efficacy and safety data that may differentiate from first generation candidates. The discussion is moderated by Altasciences' Chief Scientific Officer, Dr. Beatrice Setnik.
The potential use of psychedelics for the treatment of various CNS indications is currently under active investigation.
Up Close and Personal with Ben Reed, BS, Executive General Manager, CDMO Services
Tailored Analytical Solutions for Fast Entry into Clinical Trials
Choosing the Right Partner for Your Formulation Needs
Altasciences’ extensive formulation and manufacturing services, integrated with our early phase drug development offering, spans across the full drug development pathway, from discovery through commercialization. Our scientists have decades of expertise with both simple and complex dosage forms, and a successful track record of formulating molecules and developing the drug products required to support early phase clinical trials.
Discover our full range of analytical services, including:
- Drug product release and stability testing
- Method development, qualification, and validation
- On-site, ICH stability storage and testing
Get a head start on your project ― speak with one of our scientists.
You may also be interested in the following:
- Webpage: Pharmaceutical Contract Manufacturing Services
- Webinar: Overcoming the Challenges of Manufacturing and Clinical Trials
- Webpage: Clinical Trial Services
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Clinical Assessment of Potential Cardiac Risk for Your Drug
The thorough and precise evaluation of cardiac effects is a critical element of new chemical entity development. You can choose to add early cardiac safety assessment to your first-in-human studies, or wait and perform a Thorough QT prolongation study; either way, we can help you with the study design and conduct.
In this educational video, Dr. Beatrice Setnik, Altasciences’ Chief Scientific Officer, walks you through the differences between early and late QT prolongation testing.
Speak with our experts today for help in deciding between early and late QT prolongation testing.
You may also be interested in the following:
- Webpage: QT Assessment
- Fact Sheets:
- The Altascientist: Cardiac Clinical Trials, Global Regulatory Requirements, Design, and Timing of QT Assessment (Case Study Included)
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept.
Antisense Oligonucleotide Quantitation ― Accurate, Robust and Sensitive.
Regulated bioanalytical development for the analysis of antisense oligonucleotides (ASOs) is showing promise in therapeutic applications for a number of diseases.
From preclinical to clinical, Altasciences has significant expertise in supporting robust and sensitive bioanalytical assays that minimize interference, for accurate quantification of ASOs in complex biological tissues.
In the last couple of years, our bioanalytical scientific experts have developed close to 100 assays of various matrices, supported close to 100 preclinical and clinical studies at various stages, and analyzed over 15,000 samples in oligonucleotide quantitation.
Speak with an expert today to ensure you are provided with the best bioanalytical techniques for your ASO drug development program.
You may also be interested in the following:
- The Altascientist: Antisense Oligonucleotides
- Webinars:
- Webpages:
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.